Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.

Abstract: The invention relates to new olaparib oxalic acid cocrystals. The olaparib oxalic acid cocrystals vary in ratio from 1:1 to 2:3 olaparib: oxalic acid. In particular, the invention relates to a 2:3 olaparib oxalic acid cocrystal, a 1:1 olaparib oxalic acid cocrystal, and a 2:1 olaparib oxalic acid cocrystal. The invention also relates to pharmaceutical compositions containing an olaparib oxalic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib oxalic acid cocrystals of the invention may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP). These include cancer, fibrosis, inflammatory conditions (e.g. asthma, colitis, arthritis), neurological diseases (e.g. neurodegeneration, neurotrauma, stroke), cardiovascular conditions, ophthalmic degenerative diseases, vascular diseases (e.g. diabetic complications, atherosclerosis), and various forms of critical illness (e.g. septic shock, ALI, acute liver failure).

Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Abstract: The invention relates to new 1:1 olaparib:hydroxybenzoic acid cocrystals. The invention also relates to new 2:1 olaparib:hydroxybenzoic acid cocrystals which may contain no water (anhydrous) or may optionally be hydrated. The invention also relates to pharmaceutical compositions containing an olaparib hydroxybenzoic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib hydroxybenzoic acid cocrystals of the invention may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP).

Abstract: New tetrahydrocannabinolic acid cocrystals are disclosed, in particular, a 1:1 tetrahydrocannabinolic acid L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D,L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid ethyl maltol cocrystal and a 1:1 tetrahydrocannabinolic acid caffeine cocrystal. The invention also relates to pharaceutical compositions containing a tetrahydrocannabinolic acid cocrystal of the invention and a pharmaceutically acceptable carrier and methods to treat a disease, disorder or condition by administering to a patient in need thereof a therapeutically effective amount of tetrahydrocannabinolic acid cocrystal or a pharmaceutical composition containing a tetrahydrocannabinolic acid cocrystal.

Abstract: A solid form of RAD1901-2HCl having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 11.53 degrees 2?±0.2 degrees 2?, and compositions, methods, and processes thereof.

Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Abstract: Cannabigerol proline cocrystals are disclosed, specifically a 1:2 cannabigerol L-proline cocrystal, a 1:2 cannabigerol D-proline cocrystal and a 1:2 cannabigerol D, L-proline cocrystal and their preparation. Also disclosed are pharmaceutical compositions containing a cannabigerol proline cocrystal and a pharmaceutically acceptable excipient as well as methods and uses of a cannabigerol proline cocrystal or pharmaceutical composition to treat a disease, disorder or condition by administering to a patient in need thereof a therapeutically effective amount of a cannabigerol proline cocrystal or a pharmaceutical composition containing a cannabigerol proline cocrystal. Also disclosed are processes for the preparation of crystalline cannabigerol, Forms I, II and III.

Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Abstract: The present invention relates to a polymorph of venetoclax, to a process for its preparation, and to pharmaceutical compositions containing the polymorph.

Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.

Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Abstract: Various polymorphic forms of RAD1901-2HCl, including four crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Abstract: A crystalline form of a bile acid compound and methods of preparation and use thereof are described.